Postpartum hemorrhage (PPH)—or excessive bleeding after childbirth—is the leading cause of maternal mortality worldwide, and oxytocin is the first-line drug of choice for prevention and treatment. The World Health Organization (WHO) recommends oxytocin for PPH prevention and treatment, and it was included as one of the 13 priority, lifesaving health products under the UN Commission on Life-Saving Commodities for Women and Children. If used appropriately, universal access to oxytocin could save 1.4 million lives over the next 10 years. Countries around the world purchase and use oxytocin.

Developed by PATH, USAID, and the Global Health Supply Chain Program-Procurement Supply Management project, this messaging framework is intended for use by maternal and child health advocates who are communicating with government policymakers, civil society, and other stakeholders pivotal to the decision-making process around oxytocin policy, procurement, and distribution. This may include health practitioners, technical experts, government leaders, and civil society and community representatives who are concerned about women’s health and well-being.